Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

This study has been completed.
Sponsor:
Collaborator:
AGO Germany
Information provided by (Responsible Party):
West German Study Group
ClinicalTrials.gov Identifier:
NCT02115204
First received: April 8, 2014
Last updated: April 14, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2010
  Primary Completion Date: August 2005 (Final data collection date for primary outcome measure)
No publications provided by West German Study Group

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):